Study identifier:4522IL/0068
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with type IIa and IIb Hypercholesterolemia.
Hypercholesterolemia
Phase 3
No
Rosuvastatin, Atorvastatin, Simvastatin
All
4875
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Rosuvastatin | - |
Active Comparator: 2 Atorvastatin | - |
Active Comparator: 3 Simvastatin | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.